Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Maria Antonietta Bali
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Maria-Antonietta Bali wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Review New challenges in perioperative management of pancreatic cancer. 2015

Puleo, Francesco / Maréchal, Raphaël / Demetter, Pieter / Bali, Maria-Antonietta / Calomme, Annabelle / Closset, Jean / Bachet, Jean-Baptiste / Deviere, Jacques / Van Laethem, Jean-Luc. ·Francesco Puleo, Raphaël Maréchal, Annabelle Calomme, Jean Closset, Jacques Deviere, Jean-Luc Van Laethem, Department of Gastroenterology and Digestive Oncology, Erasme Hospital, 1070 Brussels, Belgium. ·World J Gastroenterol · Pubmed #25741134.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the industrialized world. Despite progress in the understanding of the molecular and genetic basis of this disease, the 5-year survival rate has remained low and usually does not exceed 5%. Only 20%-25% of patients present with potentially resectable disease and surgery represents the only chance for a cure. After decades of gemcitabine hegemony and limited therapeutic options, more active chemotherapies are emerging in advanced PDAC, like 5-Fluorouracil, folinic acid, irinotecan and oxaliplatin and nab-paclitaxel plus gemcitabine, that have profoundly impacted therapeutic possibilities. PDAC is considered a systemic disease because of the high rate of relapse after curative surgery in patients with resectable disease at diagnosis. Neoadjuvant strategies in resectable, borderline resectable, or locally advanced pancreatic cancer may improve outcomes. Incorporation of tissue biomarker testing and imaging techniques into preoperative strategies should allow clinicians to identify patients who may ultimately achieve curative benefit from surgery. This review summarizes current knowledge of adjuvant and neoadjuvant treatment for PDAC and discusses the rationale for moving from adjuvant to preoperative and perioperative therapeutic strategies in the current era of more active chemotherapies and personalized medicine. We also discuss the integration of good specimen collection, tissue biomarkers, and imaging tools into newly designed preoperative and perioperative strategies.

2 Article Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST. 2018

Bali, Maria Antonietta / Pullini, Serena / Metens, Thierry / Absil, Julie / Chao, Shih-Li / Marechal, Raphael / Matos, Celso / Peerboccus, Bibi Mooneera / Van Laethem, Jean-Luc. ·Department of Radiology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, 1070 Brussels, Belgium. Electronic address: mbali@ulb.ac.be. · Institute of Diagnostic Radiology, University of Udine, Udine, Italy. Electronic address: serepul@libero.it. · Department of Radiology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, 1070 Brussels, Belgium. Electronic address: tmetens@ulb.ac.be. · Department of Radiology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, 1070 Brussels, Belgium. Electronic address: Julie.absil@erasme.ulb.ac.be. · Department of Radiology, Institute Jules Bordet, Boulevard de Waterloo, 121, 1000 Brussels, Belgium. Electronic address: chih-li.chao@bordet.be. · Department of Gastroenterology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, 1070 Brussels, Belgium. Electronic address: Raphael.Marechal@erasme.ulb.ac.be. · Department of Radiology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, 1070 Brussels, Belgium. Electronic address: cmatos@ulb.ac.be. · Department of Radiology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, 1070 Brussels, Belgium. Electronic address: Bibi.Peerboccus@erasme.ulb.ac.be. · Department of Gastroenterology, Erasme Hospital, Université Libre de Bruxelles, Route de Lennik, 808, 1070 Brussels, Belgium. Electronic address: JL.VanLaethem@erasme.ulb.ac.be. ·Eur J Radiol · Pubmed #29857866.

ABSTRACT: PURPOSE: To prospectively assess chemotherapy-induced changes in pancreatic ductal adenocarcinoma (PDA) with diffusion-weighted (DW)-MR quantitative metrics, including apparent diffusion coefficient (ADC) and histogram-derived parameters, compared with RECIST 1.1. METHODS: 24 patients underwent DW-MR at baseline, week-2 and week-8 after chemotherapy initiation. Tumour diameter was assessed on T2-weighted images. Regions-of-interest (ROI) were drawn on ADC map for ROI-ADC. Volume segmentation (b = 1000 s/mm RESULTS: 15/24 patients were responders. RECIST 1.1 correctly characterized 6/15 responders at week-8. At week-2, in responders DW-volume decreased (P = .002); ROI-ADC mean H-D increased (P = .047; P = .048;). The 25th percentile H-D increased in responders and decreased in non-responders (P = .016; P = .048). At week-8 in responders DW-volume decreased and ROI-ADC mean, 25th, 50th, 75th percentiles of H-ADC and H-D increased (P < .05). No changes were observed in non-responders (P > .05). At week-2, 25th percentile of H-D and H-PF relative change correctly classified 20/24 patients (P = .003); at week-8, DW-volume relative change correctly classified 22/24 patients (P < .0001). CONCLUSIONS: ROI-ADC, DW-volume and histogram-derived diffusion parameters are more accurate to categorize responding and non-responding PDA patients treated with chemotherapy compared with RECIST 1.1.